Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Iterum Therapeutics ( (ITRM) ) just unveiled an update.
On February 24, 2026, Iterum Therapeutics disclosed that it had received a Nasdaq delisting determination after failing to meet the $1.00 minimum bid price requirement, with trading in its ordinary shares set to be suspended on March 5, 2026, absent a successful appeal to a Nasdaq Hearings Panel. The company also remains out of compliance with Nasdaq’s market value and equity or income standards, and, amid constrained access to capital, is weighing options that include a potential wind-down or bankruptcy in which shareholders are unlikely to recover meaningful value, as well as a possible move to end its SEC reporting obligations following delisting.
These developments underscore severe financial strain and raise the likelihood that Iterum’s equity could become effectively worthless, significantly eroding investor confidence and narrowing strategic options. The prospect of delisting, coupled with consideration of liquidation or similar proceedings, marks a critical juncture for the company’s future operations and its standing within the biopharmaceutical industry.
The most recent analyst rating on (ITRM) stock is a Hold with a $0.31 price target. To see the full list of analyst forecasts on Iterum Therapeutics stock, see the ITRM Stock Forecast page.
Spark’s Take on ITRM Stock
According to Spark, TipRanks’ AI Analyst, ITRM is a Neutral.
The score is held down primarily by weak financial fundamentals (minimal revenue, persistent losses, cash burn, and negative equity) and bearish technicals (price below major moving averages with negative MACD). The earnings call adds some support due to early launch traction and 2026 revenue guidance, but this is tempered by the need for additional capital, while the Nasdaq listing compliance issue adds further downside risk.
To see Spark’s full report on ITRM stock, click here.
More about Iterum Therapeutics
Iterum Therapeutics plc is a biopharmaceutical company focused on developing and commercializing anti-infective therapies, with its ordinary shares previously listed on the Nasdaq Capital Market. The company targets unmet medical needs in infectious diseases, positioning itself within a highly capital-intensive and regulation-driven segment of the healthcare sector.
Average Trading Volume: 762,821
Technical Sentiment Signal: Sell
Current Market Cap: $13.97M
Find detailed analytics on ITRM stock on TipRanks’ Stock Analysis page.